JM-20 administration to animals with lesion of the nigrostriatal dopamine pathway induced by 6-hydroxydopamine, partially reverses motor damage and oxidative stress

Luis Arturo Fonseca-FonsecaLaura Reina Taño PortuondoJeney Ramírez-SánchezNancy Pavón FuentesAbel Mondelo RodríguezVíctor Diógenes Amaral da SilvaSílvia Lima CostaYanier Núñez-Figueredo2026-03-222026-03-22202510.1080/01616412.2025.2490089https://doi.org/10.1080/01616412.2025.2490089https://andeanlibrary.org/handle/123456789/76959Our study provides the preclinical evidence to support the long-term neuroprotective potential of JM-20 in 6-OHDA hemiparkinson rat model, pointing out to its possible use as a disease-modifying agent in PD.enPars compactaSubstantia nigraDopamineNeuroprotectionHydroxydopamineStriatumOxidative stressOxidopamineLesionParkinson's diseaseJM-20 administration to animals with lesion of the nigrostriatal dopamine pathway induced by 6-hydroxydopamine, partially reverses motor damage and oxidative stressarticle